Barole

Barole Dosage/Direction for Use

rabeprazole

Manufacturer:

Mega Lifesciences

Distributor:

Maxxcare
Full Prescribing Info
Dosage/Direction for Use
Capsule: Barole should be administered before meals.
Adults: Healing of Erosive or Ulcerative GERD: Recommended Dose: One 20-mg cap once daily for 4-8 weeks.
Maintenance for Healing of Erosive or Ulcerative GERD (GERD Maintenance): Recommended Dose: One 20-mg cap once daily.
Healing of Duodenal Ulcers: Recommended Dose: One 20-mg cap once daily after the morning meal for a period up to 4 weeks. Most patients with duodenal ulcer heal within 4 weeks.
Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: The dosage varies with the individual patient. Recommended Starting Dose: 60 mg once a day. Doses should be adjusted to individual patient's needs and should be continued as long as clinically indicated. Doses up to 100 mg four times daily and 60 mg twice daily have been administered.
No dosage adjustment is necessary in elderly patients, in patients with renal disease or in patients with mild to moderate hepatic impairment. Administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.
Barole capsules should be swallowed whole. The capsules should not be chewed, crushed or split.
Injection: Recommended Dose: 1 vial (rabeprazole 20 mg) once daily.
The content of the vial needs to reconstituted with sterile water for injection 5 mL which should be given slowly over 5-15 min. 
Infusion: For IV infusion the reconstituted solution should be further diluted and administered as short-term infusion over 15-30 min.
Compatibility with Various IV Fluids: Barole injection is compatible with dextrose injection, dextrose saline injection. 
Special Populations: No dosage adjustment is necessary in elderly patients, in patients with renal disease or in patients with mild to moderate hepatic impairment. Administration of rabeprazole to patients with mild to moderate liver impairment results in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in these patients.
Administration: The IV administration is recommended only in cases where the oral administration is not indicated. As soon as an oral therapy is possible the IV therapy should be discontinued. 
Parenteral routes of administration other than IV are not recommended.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in